T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Merlini, Esther ^a   Luzi, Kety ^a   Suardi, Elisa ^a   Barassi, Alessandra ^a   Cerrone, Maddalena ^a   Martínez, Javier Sánchez ^a   Bai, Francesca ^a   D'Eril, Gian Vico Melzi ^a   Monforte, Antonella D'Arminio ^a   Marchetti, Giulia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; FAS ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LIPOPOLYSACCHARIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ULTRASOUND; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CHI SQUARE TEST; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; ECHOGRAPHY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; INFLAMMATION; KRUSKAL WALLIS TEST; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PREDICTION; RANK SUM TEST; SENESCENCE; T LYMPHOCYTE ACTIVATION; VIROLOGY;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; APOPTOSIS; ATHEROSCLEROSIS; CAROTID ARTERIES; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES;

EID: 84866923510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046073     Document Type: Article

References (53)

1. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, et al. (2008) Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118: e29-35.
2. Savès M, Chêne G, Ducimetière P, Leport C, Le Moal G, et al. (2003) Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37: 292-298.
3. Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, et al. (2011) The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 4: 425-432.
4. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356: 1723-1735.
5. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426.
6. Kowalska JD, Kirk O, Mocroft A, Høj L, Friis-Møller N, et al. (2010) Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV Med 11: 200-208.
7. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, et al. (2010) Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318-330.
8. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, et al. (2010) Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 170: 1228-1238.
9. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, et al. (2009) Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 51: 20-28.
10. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, et al. (2010) Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 11: 130-136.
11. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL, (2011) Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 57: 245-253.
12. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, et al. (2009) Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 49: 1119-1127.
13. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, et al. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23: 929-939.
14. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
15. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA, (2011) Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 214: 468-473.
16. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, et al. (2011) T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 203: 452-463.
17. Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, et al. (2003) Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 89: 1411-1415.
18. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, et al. (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96: 4219-4225.
19. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, et al. (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101: 2149-2153.
20. Amar J, Fauvel J, Drouet L, Ruidavets JB, Perret B, et al. (2006) Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 24: 1083-1088.
21. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, et al. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610.
22. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
23. Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, et al. (2008) Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22: 2035-2038.
24. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, et al. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 199: 1177-1185.
25. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, et al. (2008) Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 3: e1915.
26. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, et al. (2010) Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115: 161-167.
27. Stoll LL, Denning GM, Weintraub NL, (2004) Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 24: 2227-2236.
28. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, et al. (1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 34: 1975-1981.
29. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, et al. (2010) Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 5: e8886.
30. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, et al. (2006) Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 20: 2275-2283.
31. Vamvakopoulos J, Häyry P, (2003) Cytomegalovirus and transplant arteriopathy: evidence for a link is mounting, but the jury is still out. Transplantation 75: 742-743.
32. Parrinello CM, Sinclair E, Landay AL, Lurain N, Sharrett AR, et al. (2012) Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis 205: 1788-1796.
33. Salonen JT, Salonen R, (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87: II56-65.
34. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, et al. (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146: 483-494.
35. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947.
36. Salazar-Gonzalez JF, Martinez-Maza O, Aziz N, Kolberg JA, Yeghiazarian T, et al. (1997) Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection. Clin Immunol Immunopathol 84: 36-45.
37. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, et al. (1996) Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 10: 827-834.
38. Palmer BE, Blyveis N, Fontenot AP, Wilson CC, (2005) Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol 175: 8415-8423.
39. Weng NP, Akbar AN, Goronzy J, (2009) CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol 30: 306-312.
40. Nadareishvili ZG, Li H, Wright V, Maric D, Warach S, et al. (2004) Elevated pro-inflammatory CD4+CD28- lymphocytes and stroke recurrence and death. Neurology 63: 1446-1451.
41. Strioga M, Pasukoniene V, Characiejus D, (2011) CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 134: 17-32.
42. Bandrés E, Merino J, Vázquez B, Inogés S, Moreno C, et al. (2000) The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol 96: 230-235.
43. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, et al. (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 98: 2817-2827.
44. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, et al. (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720.
45. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, et al. (1996) Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10: F17-22.
46. Paulsen M, Janssen O, (2011) Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal 9: 7.
47. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
48. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, et al. (2001) Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103: 1064-1070.
49. Manco M, Putignani L, Bottazzo GF, (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817-844.
50. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, et al. (2011) Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141: 1220-1230, 1230.e1221-1223.
51. Ho JE, Hsue PY, (2009) Cardiovascular manifestations of HIV infection. Heart 95: 1193-1202.
52. Rossi R, Nuzzo A, Guaraldi G, Orlando G, Squillace N, et al. (2009) The role of the Framingham risk score to predict the presence of subclinical coronary atherosclerosis in patients with HIV infection. J Acquir Immune Defic Syndr 52: 303-304.
53. Aiello AE, Simanek AM, (2012) Cytomegalovirus and immunological aging: the real driver of HIV and heart disease? J Infect Dis 205: 1772-1774.